Intermittent explosive disorder: epidemiology, diagnosis and management

CNS Drugs. 2002;16(8):517-26. doi: 10.2165/00023210-200216080-00002.

Abstract

Intermittent explosive disorder (IED) is characterised by discrete episodes of aggressive impulses that result in serious assaultive acts towards people or destruction of property. IED causes severe impairments in daily function. The diagnosis of IED should be made only after a thorough medical work-up. A structured or semi-structured diagnostic interview is helpful to ensure that comorbid and pre-existing conditions are considered. There is a lack of controlled trials of agents for the treatment of patients with IED, but there is evidence that mood stabilisers, antipsychotics, beta-blockers, alpha(2)-agonists, phenytoin and antidepressants may be useful. Behavioural interventions may be valuable as part of the overall treatment of IED.

Publication types

  • Review

MeSH terms

  • Adrenergic Agents / therapeutic use
  • Anticonvulsants / therapeutic use
  • Antidepressive Agents / therapeutic use
  • Antipsychotic Agents / therapeutic use
  • Behavior Therapy / methods
  • Disruptive, Impulse Control, and Conduct Disorders / diagnosis*
  • Disruptive, Impulse Control, and Conduct Disorders / drug therapy
  • Disruptive, Impulse Control, and Conduct Disorders / epidemiology
  • Disruptive, Impulse Control, and Conduct Disorders / therapy*
  • Humans
  • Lithium / therapeutic use
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Treatment Outcome

Substances

  • Adrenergic Agents
  • Anticonvulsants
  • Antidepressive Agents
  • Antipsychotic Agents
  • Serotonin Uptake Inhibitors
  • Lithium